The protocol will be deployed at three sites in the same geographical location. The
design encompasses weekly monitoring of asymptomatic, non- disease populations, confirmed
by RT-PCR for presumed positive cases. Each positive case will be followed with daily
antigen testing and matched RT-PCR testing for 8 consecutive days in accordance with the
CDC's stay-at-home protocol, the positive case will quarantine according to public
policy. In addition to asymptomatic participants, participants presenting with a positive
The antigen tests that will be utilized are all commercial final products with a CE mark.

All antigen tests utilized are close to identical procedure. Appendix 1 shows the
instructions for use of each of the tests. All tests determined nucleoprotein of SARS
CoV-2 in a qualitative manner.

Participants are not expected to participate beyond sample collection and processing of
rapid antigen test as part of the study. The collection of one anterior nares sample is
done once a week. A second nasal swab will be done once a sample indicates presumptive
positive for COVID-19. At the end of 4 months of the study we will provide a rate of
positive cases over time, and a positive agreement value over 8 days of testing of a
positive case. The data will include a Positive Percent Value (PPV) and potentially
expand to provide a NPV when negative samples are sent to the CLIA lab to determine the
specificity of the tests.

In order to be eligible to participate in this study, an individual must meet all of the
following criteria:

1. Individuals 12 year of age or older

2. Provision of paper-consent form and acceptance of participating on a volunteer
basis.

Eligible affiliates are individuals who are associated to the member communities of each
site and who are identified and consented into the study. These may be individuals who
are in close contact with the member community and thus seen as peripheral community
members.

- Subjects will be approached by research staff to determine if they would be
interested in participating in this study. If willing, a qualified study team member
will consent the subject. The electronic system will keep the information about
approval of the informed consent by participant. We will also keep a record of the
paper and a digital photo of the same document.

- Study staff will provide instructions to participants in the sample collection
procedures on site to ensure proper self-sample collection and to minimize the risk
of sample contamination. At the time of initial training. The participant will be
using a self-swabbing process to obtain the NA sample. If we encounter an impediment
for self-swabbing, the process will be done by assisting the participant.

- There will be 3 sites in the same geographical location. The design encompasses
weekly monitoring of asymptomatic, non- disease populations by antigen test.The
positive case will be followed with daily PCR / antigen test testing for 8
consecutive days in accordance with the CDC's stay-at-home protocol, each quarantine
period will be completed. This screening will be used for assessing positive cases
and confirming using a CLIA lab authorized molecular test.

- All materials part of the COVID-19 antigen test kit will be provided by the sponsor
(Manufacturers provide the test to the sponsors). The test cassettes will be kept at
Room Temperature.

SCIENTIFIC RATIONALE FOR STUDY DESIGN

The testing of asymptomatic cases to mitigate COVID-19 Pandemic requires frequent use in
the population. Lateral flow bioassays are relatively inexpensive to manufacture, easy to
store, and easy for front line use in public setting.

END OF STUDY DEFINITION

Participants are not expected to participate beyond frequent sample collection and
processing of rapid antigen test as part of the study. The collection of anterior nares
sample will be done once a week, as well as daily testing for up to 8 days in case of
positive PCR result.

STUDY POPULATION

INCLUSION CRITERIA

1. Individuals age 12 or older

2. Provision paper-consent and acceptance of participating on a volunteer basis.

Up to 450 residents at:

Margolis Apartments (Federal Elderly/Disabled) - A 152- unit thirteen-story brick
structure for elderly and/or disabled residents

Buckley Apartments (State Elderly/Disabled) - Located at 14 Bloomingdale Street has 210
one-bedroom apartments

Housing at 242 Walnut Street (State Elderly/Disable 40 Units

Affiliates are individuals who are associated to the member communities of The Chelsea
Project sites and who are identified and consented into the study. These may be
individuals who are in close contact with the member community and thus seen as
peripheral community members.

EXCLUSION CRITERIA

If the participant requires medical urgent attention at the site of collection.

PARTICIPANT DISCONTINUATION/WITHDRAWAL

DISCONTINUATION OF STUDY SAMPLE EVALUATION

Subjects may withdraw at any time and request that their samples not be processed.

STUDY ASSESSMENTS AND PROCEDURES

STUDY PROCEDURES

All materials will be provided by the sponsor (IDx20-CCI) along with the co-sponsors
owners of the test cassettes. The test cassettes should be kept at Room Temperature until
use and in an indoor environment.

1. Subjects will be approached by research staff to determine if they would be
interested in participating in this study. If willing, a qualified study team member
will conduct a paper or e-informed consent process with the subject. The detailed
procedure to conduct the test will be provided (insert) for each type of test each
week. In two lenguages. The electronic system will populate the information about
approval of the verbal informed consent by participant and it will provide a digital
step by step instructions.

2. Study staff will provide support to participants to obtain the instructions and
materials for sample collection procedures on site at each of the Chelsea Project
sites to ensure proper sample collection and to minimize the risk of sample
contamination.

3. The building administrator will have information of a presumptive positive case.
Each site will follow their approved procedures for quarantine once the participant
has been confirmed by RT-PCR. The participant will be tested at home each day after
contracting COVID-19 for the following 8 days. The samples for PCR confirmation will
be collected at home and sent to a CLIA lab.

Participant confidentiality and privacy is strictly held in trust by the participating
investigators, their staff, and the sponsor(s) and their interventions. This
confidentiality is extended to cover testing of biological samples in addition to any
clinical information relating to participants. Therefore, the study protocol,
documentation, data, and all other information generated will be held in strict
confidence. No information concerning the study, or the data will be released to any
unauthorized third party without prior written approval of the sponsor.

The study monitor, other authorized representatives of the sponsor, representatives of
the Institutional Review Board (IRB), regulatory agencies or pharmaceutical company
supplying study product may inspect all documents and records required to be maintained
by the investigator, including but not limited to, medical records (office, laboratory
facility).

The study participant's contact information will be securely stored at each site for
internal use during the study. At the end of the study, all records will continue to be
kept in a secure location for as long a period as dictated by the reviewing IRB,
Institutional policies, or sponsor requirements.

Study participant research data, which is for purposes of statistical analysis and
scientific reporting, will be transmitted to and stored at the The Chelsea Project
server. A designed application will be used for the collection of cassette result images.
This will not include the participant's contact or identifying information and includes
participant ID numbers only. Rather, individual participants and their research data will
be identified by a unique study identification number. The study data entry and study
management systems used by study sites and by sponsor research staff will be secured and
password protected. At the end of the study, all study databases will be de-identified
and archived at the sponsor facilities.

FUTURE USE OF STORED SPECIMENS AND DATA

The nasal swab collected in saline will be required for RT-PCR confirmation, these
samples will be stored at the CLIA lab (EcoLaboratory. Acton Ma). After the study is
completed, the de-identified, archived data will be for use by other researchers as
determined by sponsor only.

The data of the study could be used for research purposes.

During the conduct of the study, an individual participant can choose to withdraw consent
to have biological specimens stored for future research. However, withdrawal of consent
with regard to bio sample storage may not be possible after the study is completed.